London, UK; Brentwood, TN, US: 8 February 2008 - Protherics PLC ("Protherics" or
the "Company"), the international biopharmaceutical company focused on critical
care and cancer, in accordance with Listing Rule 3.5.6, notifies the following
details in respect of a block listing for the Company's 6% Unsecured Convertible
Loan Notes:
